ESR1 and inflammatory breast carcinoma: Importantly, IBC patients with triple-negative (ER-/PR-Her2-) tumors had a significant (P<0.0001) overall worse survival rate (36% [90% CI: 0.11-0.62]) (Fig. 1E).